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Abstract
Background: Monovalent varicella vaccines have been available in the Veneto Region of Italy since 2004. In 2006, a
single vaccine dose was added to the immunisation calendar for children aged 14 months. ProQuad®, a quadrivalent
measles-mumps-rubella-varicella vaccine, was introduced in May 2007 and used, among other varicella vaccines, until
October 2008. This study aimed to evaluate the effectiveness of a single dose of ProQuad, and the population impact
of a vaccination program (VP) against varicella of any severity in children who received a first dose of ProQuad at
14 months of age in the Veneto Region,
Methods: All children born in 2006/2007, i.e., eligible for varicella vaccination after ProQuad was introduced, were
retrospectively followed through individual-level data linkage between the Pedianet database (varicella cases) and the
Regional Immunization Database (vaccination status). The direct effectiveness of ProQuad was estimated as the
incidence rate of varicella in ProQuad-vaccinated children aged < 6 years compared to children with no varicella
vaccination from the same birth cohort. The impact of the VP on varicella was measured by comparing children
eligible for the VP to an unvaccinated historical cohort from 1997/1998. The vaccine impact measures were: total effect
(the combined effect of ProQuad vaccination and being covered by the Veneto VP); indirect effect (the effect of the VP
on unvaccinated individuals); and overall effect (the effect of the VP on varicella in the entire population of the Veneto
Region, regardless of their vaccination status).
Results: The adjusted direct effectiveness of ProQuad was 94%. The vaccine impact measures total, indirect, and overall
effect were 97%, 43%, and 90%, respectively.
Conclusions: These are the first results on the effectiveness and impact of ProQuad against varicella; data confirmed its
high effectiveness, based on immunological correlates for protection. Direct effectiveness is our only ProQuad-specific
measure; all impact measures refer at least partially to the VP and should be interpreted in the context of high vaccine
coverage and the use of various varicella vaccines in this region. The Veneto Region offered a unique opportunity for
this study due to an individual data linkage between Pedianet and the Regional Immunization database.
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Background
Varicella-zoster virus is the causal agent of varicella
(chickenpox) and herpes zoster (shingles). Varicella is
predominantly a childhood disease in unvaccinated pop-
ulations, with a lifetime risk of acquisition of over 95%.
Varicella is highly contagious, with secondary attack
rates of 60% to 100% in susceptible individuals [1]. Al-
though varicella is commonly considered a mild disease,
it may cause serious complications [2] and represents a
sizeable societal burden for patients and their caregivers,
sometimes leading to school and work absence [3].
Varicella vaccines have proven to be effective in pre-
venting varicella. Models of the economic impact of
childhood varicella vaccination have been performed in
Italy, France, and Germany and have projected that rou-
tine vaccination programmes could dramatically reduce
varicella-related morbidity and lead to a decrease in the
number of varicella-related deaths (ranging from 57% to
87% across different strategies and settings) [4, 5]. A vac-
cine coverage of 90% is projected to lead to savings from
both a societal (40% to 60%) and a third-party payer (7%
to 61%) perspective [4, 5]. The World Health Organisa-
tion advocates routine childhood immunisation against
varicella in countries where the disease is an important
public health and socioeconomic problem, where the
vaccine is affordable, and where high (≥80%) vaccine
coverage can be achieved and sustained [6].
In 1974, Takahashi and colleagues developed an atten-
uated strain of the varicella virus at the University of
Osaka, called the OKA strain. Several monovalent and
combined live attenuated varicella vaccines that are cur-
rently authorised in Europe were derived from this
strain. These include the two monovalent vaccines: Vari-
vax® (OKA/Merck strain, Merck & Co., Westpoint,
United States) and Varilrix® (OKA/RIT strain, GlaxoS-
mithKline, Rixensart, Belgium), which were licensed in
Europe in the 1990s, and two combined live attenuated
quadrivalent vaccines against measles, mumps, rubella,
and varicella (MMRV): ProQuad® (OKA/Merck strain,
Merck & Co.) and Priorix Tetra® (OKA/RIT strain, Glax-
oSmithKline), which were licensed in Europe as from
2006. The quadrivalent vaccines were developed to fa-
cilitate childhood vaccination programmes and to sup-
port the implementation of routine varicella vaccination.
Clinical trials on ProQuad demonstrated that one dose
of the vaccine was immunologically comparable to con-
comitant administration of the M-M-R®II vaccine
(Merck & Co.), a combined measles, mumps, and rubella
vaccine, and Varivax [7, 8]. However, there have been no
formal studies on the efficacy or effectiveness of
ProQuad.
The Veneto Region is located in Northeastern Italy.
Monovalent varicella vaccines have been available for
private purchase there since 2004, and they were
introduced into the vaccination programme (free of
charge) in 2006 for children aged 14 months (2005 birth
cohort). Catch-up vaccination was also included for
those aged 12 years (1994 birth cohort) with no history
of varicella [9]. In 2008, the Veneto Region added a sec-
ond dose of varicella vaccine to the vaccination
programme, which is to be administered at 6 years of
age.
From 2004 to April 2007 in the Veneto Region, a
monovalent varicella vaccine, mostly Varivax but also
Varilrix, was usually administered concomitantly with
the first dose of the measles-mumps-rubella vaccine. In
May 2007, the Veneto Region was using ProQuad as a
first dose, and in 2008 it began to use it for the second
dose as well. However, in October 2008 ProQuad be-
came unavailable and was replaced by the quadrivalent
vaccine Priorix Tetra. Monovalent varicella vaccines
were also distributed and administered throughout the
above-mentioned period (Fig. 1).
In July 2012, the Italian Ministry of Health recom-
mended concomitant injection of a measles-mumps-
rubella vaccine and a monovalent varicella vaccine at age
14 months, due to concerns over a small increase in fe-
brile convulsions when injecting MMRV vaccines as a
first dose [10]. The use of MMRV vaccines was reserved
for the second dose at age 6, where no safety concern
had been observed.
The aim of our study was to evaluate the effectiveness
of a single dose of ProQuad, and the population impact
of a vaccination program against varicella of any severity
in children who received a first dose of ProQuad at
14 months of age in the Veneto Region of Italy.
Methods
Study setting
The Veneto Region is the fifth-largest region in Italy
(after Lombardy, Campania, Lazio, and Sicily) with 21
Local Health Authorities (LHAs) and just over 4.9 mil-
lion inhabitants. About 700,000 children under 14 years
of age live in the Veneto Region, with an annual birth
cohort of about 40,000 neonates [11]. After the birth of
a child, parents choose a family paediatrician (FP) as an
identified primary care provider, as per the requirements
of the Italian National Health Service (NHS). It is pos-
sible to change FPs, but NHS requirements state that a
child must always be registered with one FP. In turn,
FPs provide health care services free of charge and are
responsible for referring children 0 to 6 years of age to
NHS secondary and tertiary care when necessary.
Data sources
Pedianet
In 1999, Pedianet, an independent network of more than
400 FPs, was set up in Italy. Data from children whose
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parents have signed an informed consent are collected
and transmitted to a central Pedianet database in Padova
after anonymisation. There are 46 FPs in the Veneto Re-
gion that belong to Pedianet, representing about 8% of
the paediatricians (n = 574) in the region and covering a
catchment area of 12 LHAs (Fig. 2). These 46 FPs care
for about 52,000 children 0–14 years of age, including
an annual birth cohort of 3500 to 4500 neonates, corre-
sponding to about 10% of the regional birth cohort [11].
Veneto regional immunization database
The Veneto Regional Immunization Database stores data
on all immunisations administered in the region. All
paediatric vaccinations included in the Veneto vaccin-
ation programme are administered free of charge at the
district level by the LHAs. All LHAs record
immunisation data using the same software (the Sistema
Informativo Anagrafe Vaccinale regionale, SIAVr appli-
cation), and this data is then sent to the Regional
Immunization Database.
Data collection and linkage
The 46 FPs participating in Pedianet in the Veneto Re-
gion identified all children in their patient files who were
born in 2006/2007. The Pedianet ID numbers and corre-
sponding fiscal codes (a unique identifier for each per-
son living in Italy) for these children were then
encrypted and sent by the FP through a secure channel
to the Regional Immunization Database.
Information on the varicella vaccination status of these
children and the vaccine brand used was taken from the
Regional Immunization Database. Vaccine brand was
missing for 67% of the children, as this field was not
mandatory until 2010. We extracted information on vac-
cine type (monovalent or MMRV) whenever possible
when information on vaccine brand was missing. As
ProQuad was the only MMRV vaccine available in Italy
until October 2008, all MMRV vaccines recorded prior
this date were attributed to ProQuad. This increased the
proportion of vaccines identified as ProQuad to 35%,
and decreased the proportion of unknown vaccines to
58%. Vaccination data were then anonymised by discard-
ing the fiscal code and keeping only the Pedianet ID and
sent to Arsenàl.IT, Veneto’s Research Centre for eHealth
Innovation.
Information on the occurrence of varicella was ex-
tracted from the Pedianet database and sent with the
Pedianet ID number to Arsenàl.IT, where it was linked
to varicella vaccination data. Varicella cases recorded in
the Pedianet database are based on physician confirm-
ation only; no laboratory tests were performed.
Fig. 1 Timeline of varicella vaccine availability and vaccination programs in Veneto region of Italy in relation to study cohort vaccination periods.
MoH: Minister of Health; MMR/V: concomitant vaccination with measles, mumps, rubella vaccine and monovalent varicella vaccine
Fig. 2 Veneto region with Local Health Authorities (LHAs) that are
included in the analysis
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The study was conducted in accordance with the Dec-
laration of Helsinki, Good Pharmacoepidemiology Prac-
tice Guidelines, and local laws, rules, and regulations.
The ethics committee of the Azienda Ospedaliera of Pa-
dova reviewed the study-related documents and ap-
proved the study.
Study sample
FPs identified 9343 children from the 2006/2007 birth
cohort in their records, of whom 1720 were excluded
(Table 1). Thus the final number of children in the study
sample was 7623:
Statistical analyses
Children were followed from age 1 year until the occur-
rence of varicella, until they received the second dose of
varicella vaccine (if vaccinated), their 6th birthday, or
exit from the Pedianet database, whichever occurred
first.
Direct effectiveness of a single dose of ProQuad
We measured the direct effectiveness (i.e., protection of
vaccinee) of a single dose of ProQuad as the relative re-
duction in the incidence rate of varicella in the 2357
children who received ProQuad as a first dose of vari-
cella vaccine (ProQuad-vaccinated children) in our study
sample compared to the 912 unvaccinated children
(Fig. 3). All these children belonged to the same popula-
tion, were exposed to the same vaccination programme,
and were followed over the same time period. Direct ef-
fectiveness was calculated according to the following
formula:
VE ¼ 1− λv
λu
¼ 1−hr
where λv denotes the incidence rate in the ProQuad-
vaccinated group, λu the incidence rate in the unvaccin-
ated group and hr. the hazard ratio estimated by means
of a Cox proportional hazards model with vaccination
status as a time-dependent variable. Sex, birth cohort,
and number of visits to the FP were tested as covariates.
They were entered into the model as strata (not as ac-
tual predictors) if they caused the failure of the key as-
sumption of proportionality. To account for the
possibility that events within each LHA (or within FPs)
are correlated, a Cox proportional hazards model for
clustered events was fitted. The vaccination status of
each child was set to 0 at the beginning of follow-up and
remained at 0 throughout follow-up for unvaccinated
children. For vaccinated children vaccination status
switched 42 days after vaccination from 0 to 1.
Impact of the vaccination programme on varicella in the
Veneto region
We assessed three different vaccine impact measures:
(1)the total effect, i.e., the combined effect of ProQuad
vaccination and being covered by the vaccination
programme in the Veneto Region, thus
corresponding to the combination of direct and
indirect effects.
(2)the indirect effect, i.e., the population-level effect of
widespread vaccination on unvaccinated individuals
in the Veneto Region as a result of reduced
transmission.
(3)the overall effect, i.e., the effect of the vaccination
programme on varicella in the entire population of
the Veneto Region, regardless of their varicella
vaccination status (Fig. 3) [12].
Data from a historical cohort [13] from the pre-
vaccine era was used as the reference population. This
cohort consisted of 33,343 children aged 0–14 registered
with 35 Pedianet physicians across Italy (with an over-
representation of Veneto and Marche regions) between
1 October 1997 and 30 September 1998, of whom
21,783 were estimated to be susceptible to varicella. Inci-
dence rates among unvaccinated subjects from the same
historical birth cohort were calculated by dividing re-
ported numbers of varicella by estimated person-years.
The person-years were estimated based on the number
of susceptible children and varicella cases reported in
the historical cohort [13] with assumption of uniform
Table 1 Reasons for exclusion
Reasons for exclusiona Number of children
Failure to register in the Pedianet database before 6 months of age 683
No visit to FP in the first year of life 430
< 4 visits to FP in the first 6 years of life 389
Varicella diagnosis in the first year of life 200
Varicella immunisation in the first year of life 26
Received varicella vaccination from FP/missing date of varicella vaccination 16
FP family paediatrician
asome of the children had more than one reason for exclusion
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distribution for the onset of the disease, i.e., a child who
did not have a varicella diagnosis contributed a full year of
exposed person-time, while a child diagnosed with vari-
cella contributed only 6 months of exposed person-time.
Total effect The estimation of the total effect of the
vaccination programme in the Veneto Region was evalu-
ated by comparing the observed incidence rate of vari-
cella in the first 6 years of life among the 2357
ProQuad-vaccinated children to corresponding inci-
dence rates from the historical cohort (Fig. 3). It was cal-
culated according to the following formula:
VE ¼ 1− λv
λp
¼ 1−RR
Where λv denotes the varicella incidence rate among
ProQuad-vaccinated children and λp represents the rate
in the unvaccinated historical cohort. The relative risk
(RR) denotes the ratio of the varicella incidence rate
among ProQuad-vaccinated children to the susceptibility-
adjusted incidence rate in the pre-vaccination period [13].
RR and corresponding 95% confidence intervals (CIs)
were estimated with the Mantel-Haenszel method for inci-
dence rates. Vaccinated person-time was calculated from
date of first varicella vaccination plus 42 days to date of
first censoring event, allowing for the delayed onset of im-
munity after vaccination.
Indirect effect In order to evaluate the indirect effect,
the incidence rate of varicella in the 912 unvaccinated
children in our study sample was compared to incidence
rates from the historical cohort [13] (Fig. 3). The indirect
effect was defined as:
VE ¼ 1− λu
λp
¼ 1−RR
where λu denotes the incidence rate in unvaccinated
children, λp the incidence rate in the historical cohort,
and RR the incidence rate ratio. RR and corresponding
95% CIs were estimated with the Mantel-Haenszel
method for incidence rates. Unvaccinated person-time
was calculated from age 1 year until either a first dose of
ProQuad or first censoring event, whichever occurred
first.
Overall effect In order to evaluate the overall effect, the
incidence rate of varicella among all 7623 children
(vaccinated and unvaccinated) in our study sample was
compared to incidence rates from the historical cohort
(Fig. 3) [13]. The overall effect was defined as follows:
VE ¼ 1− λoverall
λp
¼ 1−RR
where λoverall denotes the average incidence rate in the
population covered by the vaccination programme, λp
the incidence rate in the historical cohort, and RR the
incidence rate ratio. RR and corresponding 95% CIs were
estimated with the Mantel-Haenszel method for inci-
dence rates. Person-time was calculated from age 1 year
until date of first censoring event.
Results
Among the 7623 children in our study sample, 6711
(88%) were vaccinated against varicella. Among vacci-
nated children, 2357 (35.1%) received ProQuad and 4354
(64.9%) received a different varicella-containing vaccine
(Varivax, Varilrix, Priorix Tetra, or an unknown brand).
Our unvaccinated population numbered 912 (Fig. 4). We
compared sex distribution, birth cohort (2006 and 2007)
and the affiliation to different LHAs in vaccinated and
unvaccinated children in our study sample. The sex
distribution was equal in both populations and no differ-
ence was observed in the distribution of vaccinated and
unvaccinated children across the two birth cohorts.
Fig. 3 Types of effect and choice of populations
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Among the 2357 ProQuad-vaccinated children, 43
varicella cases were reported, compared to 287 cases
among the 912 unvaccinated children. Of these 287
varicella cases, 110 occurred between 12 and <
24 months of age, 34 occurred in children aged 24 to
< 36 months, 58 in children 36 to < 48 months of
age, 41 cases in children aged 48 to < 60 months and
44 cases occurred in children between 60 and <
72 months of age. Among ProQuad-vaccinated chil-
dren, only two varicella cases occurred in the second
and third year of life, 16 in the fourth, 9 in the fifth
and 14 in the sixth. No varicella cases were observed
during the first 42 days after vaccination.
Effectiveness of a single dose of ProQuad
Varicella incidence among ProQuad-vaccinated children
was 0.43 (95% CI: 0.31–0.57) per 100 person-years com-
pared to 6.37 (95% CI: 5.66–7.16) per 100 person-years
among unvaccinated children. The crude direct vaccine
effectiveness was estimated at 93% (95% CI: 90–95%)
and 94% (95% CI: 91–95%) when adjusted for number of
visits to the FP (Table 2).
Vaccine impact: Total, indirect and overall effects
When comparing the varicella incidence among
ProQuad-vaccinated children (0.43 per 100 person years,
95% CI: 0.31–0.57) with that of the historical cohort
(11.87 per 100 person-years, 95% CI: 11.22–12.54), the
total effect of ProQuad was estimated at 97% (95% CI:
96–98%) (Table 2).
When comparing the varicella incidence among the
unvaccinated children (6.37 per 100 person-years, 95%
CI: 5.66–7.16) in our study cohort to that of the histor-
ical cohort, an indirect effect of 43% (95% CI: 35–50%)
was estimated (Table 2).
The overall effect was calculated by comparing the
average incidence among both vaccinated and unvaccin-
ated children in our study sample (1.2 per 100 person-
years, 95% CI: 1.09–1.32) with that of the historical co-
hort, yielding an overall effect of 90% (95% CI: 89–91%)
(Table 2).
Fig. 4 Flow chart
Table 2 Summary of vaccine effectiveness and population
impact results
Vaccine effect VE 95% CI
Direct effectiveness
Crude 0.93 (0.90–0.95)
Adjusted 0.94 (0.91–0.95)
Total effect 0.97 (0.96–0.98)
Indirect effect 0.43 (0.35–0.50)
Overall effect 0.90 (0.89–0.91)
VE please define, CI confidence interval
Giaquinto et al. BMC Infectious Diseases  (2018) 18:103 Page 6 of 9
Discussion
To the best of our knowledge, this study was the first
to measure ProQuad-specific effectiveness and the
impact of a vaccination programme against varicella
in children vaccinated with the quadrivalent MMRV
vaccine ProQuad. The Veneto Region of Italy offered
a unique possibility to conduct this study for two
reasons. First, the region is covered by the Pedianet
network, which includes data generated by FPs during
routine patient care and stored in files using a
unique, anonymised Pedianet ID that can be linked
through the fiscal code to data from the Regional
Immunization Database, where all vaccination data
are stored. Second, the Veneto Region was the only
place in Europe where the quadrivalent MMRV
vaccine ProQuad was used shortly after varicella vac-
cination was introduced into the vaccination
programme.
Values for direct effectiveness and impact were very
high, with a direct vaccine effectiveness of 93% (95% CI:
90–95%), and impacts of 97% (95% CI: 96–98%), 43%
(95% CI: 35–53%), and 90% (95% CI: 89–91%) for the
total, indirect, and overall effects, respectively, confirm-
ing the vaccine efficacy and effectiveness reported in
previous studies conducted with the monovalent vaccine
Varivax, which contains the same varicella component
as ProQuad [14].
When interpreting vaccine effectiveness and impact,
some limitations have to be considered. When estimat-
ing direct vaccine effectiveness, we made the assumption
that vaccine status was random, i.e., that the characteris-
tics of vaccinated and unvaccinated children from the
same birth cohorts did not differ. We found no differ-
ences in sex distribution or birth cohort affiliation, and
adjusted for number of visits to the FP. A further
assumption was equal susceptibility and an equal oppor-
tunity to be exposed to varicella (random mixing), which
may not always apply when incidence rates are very low.
For the measures of vaccine impact (as measured by
total, indirect, and overall effect), the study used a histor-
ical cohort to represent a pre-vaccination period [13],
assuming this cohort was reasonably similar and that the
method of collection of cases and susceptibility to varicella
did not differ between the two time periods. While we do
not know how many children in the historical cohort
came from the Veneto Region, they were all registered
with Pedianet FPs in Italy, and the Veneto Region was
over-represented. Considering that the same software used
by FPs in their routine practice (junior Bit) was used as a
data collection system in both studies, differences in data
collection should be limited. The historical cohort repre-
sents a population completely unexposed to varicella
vaccination, as the vaccine was not yet on the Italian mar-
ket, but other than this key difference, we assumed there
was no other difference in susceptibility to varicella
between the two populations.
Our historical cohort was based on the study sam-
ple from Nicolosi et al. [13]. However, these children
were only followed for 1 year. To rule out the possi-
bility that this was a high- or low-incidence year for
varicella, we performed a sensitivity analysis using the
2006/2007 birth cohorts from a neighbouring region
without a varicella vaccination programme (Lombar-
dia) registered with Pedianet as comparator and
followed them up to their 6th birthday. The total ef-
fect of 97% (95% CI: 96–98) that we obtained con-
firmed our results.
Based on a previously conducted pilot study in which
we extracted vaccination data from the Regional
Immunization Database for all children born between
2003 and 2013, we have a good picture of varicella vac-
cine coverage in the Veneto Region for these birth
cohorts. Varicella vaccines have been available in the
Veneto Region since 2004, and vaccination coverage
increased rapidly, from 15% in the 2004 birth cohort to
72% in the 2005 birth cohort, who were of vaccinating
age when the varicella vaccine became part of the Ven-
eto Region’s vaccination programme. For the 2006 to
2013 birth cohorts, vaccine coverage was high and
stable, between 83% and 90%.
The three vaccine impact measures (total, overall, and
indirect effects) relate to the vaccination programme
and depend on vaccine coverage in the population. For
the total effect we compared varicella incidence in
ProQuad-vaccinated children to that in the historical
cohort, but this effect cannot be fully attributed to Pro-
Quad. It is partly attributable to all varicella vaccines
that were administered to children between 2004 and
the end of follow-up in 2013, as it consists not only of
the direct effectiveness of the vaccine that the child
received but also the indirect protection associated with
the herd immunity that comes with increasing vaccine
coverage [12]. If the effectiveness of other varicella vac-
cines was lower than that of ProQuad, the level of
exposure to varicella of the children vaccinated with
ProQuad would be higher than expected in a hypothet-
ical cohort of children vaccinated with ProQuad only,
thus leading to an underestimation of the total effect,
that can be attributed to ProQuad. On the contrary, if
the effectiveness of other varicella vaccines was higher,
we would have observed an overestimation of the total
effect compared to a hypothetical cohort vaccinated with
ProQuad only. Therefore, the estimation of direct vac-
cine effectiveness is the best estimate of the performance
of ProQuad that is not confounded by the use of other
varicella vaccines. Indirect and overall vaccine effects are
not vaccine-specific; they are attributable to all vaccines
used in the study period.
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A general limitation of this study is that information
on vaccine brand was missing for almost 60% of the
children in our study sample. Therefore we performed a
sensitivity analysis using the same methodology as
described above, but including all vaccinated children
(whatever the brand) and compared the results to the
ProQuad-specific analyses. Crude direct vaccine effect-
iveness was 91% (95% CI: 89–93%) and 92% (95% CI:
90–93%) when adjusted for the number of visits to the
FP, and the total effect of varicella vaccination with any
brand was 95% (95% CI: 96–97%). These results are very
similar to the ones we report here; however, as the vac-
cine brand was unknown in almost 60% of vaccinated
children, and as we assume, based on procurement fig-
ures, that most of them were vaccinated with ProQuad,
we cannot draw conclusions about the potential effect-
iveness of other varicella vaccines that were used in chil-
dren in the Veneto Region in 2003–2013.
Conclusion
Our study was the first to measure the ProQuad-specific
effectiveness and impact of a vaccination program
against varicella in ProQuad-vaccinated children. Effect-
iveness and impact results were very high in the Veneto
Region, with an adjusted direct vaccine effectiveness of
94% (95% CI: 90–95%) and a total effect of 97% (95% CI:
96–98%), confirming the vaccine efficacy and effective-
ness reported in previous studies on a single dose of the
monovalent vaccine, Varivax, which contains the same
varicella component as ProQuad [15, 16]. The overall ef-
fect of the vaccination program against varicella in the
region was 90% (95% CI: 89–91%) and an indirect effect
of 43% (95% CI: 35–53%) was also demonstrated in the
unvaccinated population. For methodological reasons
the Proquad-specific vaccine effectiveness was estimated
for a single dose schedule, however, it is worth to point
out that varicella vaccination is recommended to be
given as a two dose schedule, as two vaccine doses have
been shown to result in higher seroconversion rates and
higher vaccine efficacy against both, severe and mild
disease. The Veneto Region in Italy offered a unique
opportunity to conduct this study, due to the possibility
to link information from the Regional Immunization
Database with data from the Pedianet database.
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